Literature DB >> 8538688

Induction of Plasmodium falciparum sporozoite-neutralizing antibodies upon vaccination with recombinant Pfs16 vaccinia virus and/or recombinant Pfs16 protein produced in yeast.

I I Moelans1, J Cohen, M Marchand, C Molitor, P de Wilde, J F van Pelt, M R Hollingdale, W F Roeffen, W M Eling, C T Atkinson.   

Abstract

Pfs16 is a sexual stage/sporozoite-specific antigen of Plasmodium falciparum and is a potential candidate for a sporozoite-neutralizing vaccine. To obtain more information on the function of Pfs16 and to investigate its role during transmission and hepatocyte invasion, immunization experiments were performed with both a Pfs16-specific recombinant vaccinia virus and virus-like particles produced in yeast composed of the hepatitis B surface antigen (HBsAg) and antigen Pfs16 fused to HBsAg. Upon transformation of yeast cells, harbouring a genomic copy of the HBsAg gene, with a plasmid carrying the fusion gene Pfs16-HBsAg (Pfs16-S) virus-like hybrid particles composed of HBsAg and Pfs16-S were formed of a size similar to those present in human sera after infection with the hepatitis B virus. Cells infected with recombinant Pfs16 vaccinia virus synthesized a polypeptide of approx. 16 kDa that reacted with a Pfs16-specific polyclonal antibody. Animals vaccinated with the yeast hybrid particles and/or recombinant vaccinia virus both produced Pfs16-specific antibodies. These antibodies showed no transmission-blocking activity, but they efficiently diminished or abolished in vitro invasion of sporozoites into human hepatoma cells (HepG2-A16) and primary human hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8538688     DOI: 10.1016/0166-6851(95)00072-9

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  5 in total

1.  A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.

Authors:  Eric Prieur; Sarah C Gilbert; Joerg Schneider; Anne C Moore; Eric G Sheu; Nilu Goonetilleke; Kathryn J H Robson; Adrian V S Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-23       Impact factor: 11.205

2.  A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.

Authors:  David W Porter; Fiona M Thompson; Tamara K Berthoud; Claire L Hutchings; Laura Andrews; Sumi Biswas; Ian Poulton; Eric Prieur; Simon Correa; Rosalind Rowland; Trudie Lang; Jackie Williams; Sarah C Gilbert; Robert E Sinden; Stephen Todryk; Adrian V S Hill
Journal:  Vaccine       Date:  2011-04-16       Impact factor: 3.641

3.  Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein.

Authors:  Indulis Cielens; Ludmila Jackevica; Arnis Strods; Andris Kazaks; Velta Ose; Janis Bogans; Paul Pumpens; Regina Renhofa
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.860

Review 4.  Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines.

Authors:  G P Lomonossoff; J E Johnson
Journal:  Curr Opin Struct Biol       Date:  1996-04       Impact factor: 6.809

Review 5.  Heterologous expression of plasmodial proteins for structural studies and functional annotation.

Authors:  Lyn-Marie Birkholtz; Gregory Blatch; Theresa L Coetzer; Heinrich C Hoppe; Esmaré Human; Elizabeth J Morris; Zoleka Ngcete; Lyndon Oldfield; Robyn Roth; Addmore Shonhai; Linda Stephens; Abraham I Louw
Journal:  Malar J       Date:  2008-10-01       Impact factor: 2.979

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.